Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are the newest class of antihyperglycaemic agents for type 2 diabetes mellitus (T2DM). At a Janssen-sponsored symposium in Hong Kong, Professor Jaime A. Davidson of the University of Texas Southwestern Medical Center, Dallas, Texas, US, reviewed current evidence on the SGLT-2 inhibitor class and highlighted several important differences between canagliflozin and other SGLT-2 inhibitors.
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are the newest class of antidiabetic medications with a unique mechanism of action and proven improvements in glycaemic control as monotherapy and in combination with other agents, including insulin. At the Advances in Medicine 2016 Conference organized by the Chinese University of Hong Kong, Professor Julio Rosenstock of the University of Texas Southwestern Medical Center in Dallas, Texas, US reviewed the latest data on the SGLT2 inhibitor empagliflozin (Jardiance®, Boehringer Ingelheim), with a special focus on its cardiovascular (CV), metabolic and renal benefits.
The introduction of biosimilar insulins may address the unmet demand for high quality and affordable insulin in both developing and developed countries, says an expert.
The prevalence of type 2 diabetes mellitus (T2DM) is increasing globally. Although many currently available therapies have been effective in helping T2DM patients achieve glycaemic control, many patients remain at significant risk of developing cardiovascular disease (CVD). At a Boehringer Ingelheim-sponsored symposium during the 21st Hong Kong Medical Forum organized by The University of Hong Kong (HKU), Dr. Paul Lee from HKU and Professor Lars Rydén of the Karolinska Institute, Stockholm, Sweden, discussed the potential of newer glucose-lowering agents in addressing risk factors beyond glycaemic control, highlighting the beneficial CV outcomes associated with the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin (Jardiance®, Boehringer Ingelheim).